Want to see AU:CYP full AI Analyst Report?
CYP Stock Chart & Stats
AU$0.01
>-AU$0.01(-8.33%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-8.33%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.40
Previous CloseN/A
Volume377.17K
Average Volume (3M)795.40K
Market Cap
AU$3.35M
Enterprise ValueAU$2.43M
Total Cash (Recent Filing)AU$897.42K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding334,749,760
10 Day Avg. Volume1,524,727
30 Day Avg. Volume795,400
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.41
Price to Sales (P/S)1.94
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.40M
Bulls Say, Bears Say
Bulls Say
Zero DebtZero debt removes interest and refinancing pressure, preserving flexibility to direct available resources toward clinical development and partnerships. This is a meaningful structural advantage for a loss-making biotechnology company, although it does not eliminate the need for funding.
High Gross MarginGross margin near 100% in several years indicates that reported revenue has little direct cost burden. If revenue becomes more consistent, this profile could support attractive contribution economics, allowing future commercial scale to flow through more readily before operating expenses.
Lower Cash BurnThe lower burn rate in 2026 versus 2025 indicates some improvement in cash discipline and may extend the company’s operational runway. However, the benefit is limited because both operating and free cash flow remain negative and external funding is still required.
Bears Say
Negative EquityEquity turning negative after a steep decline signals that cumulative losses have eroded the capital base. The simultaneous fall in total assets reduces financial resilience and may constrain the company’s ability to fund development without raising additional capital.
Persistent Cash BurnConsistently negative operating and free cash flow shows that the business is not yet self-funding. Continued cash consumption increases dependence on external financing to sustain clinical programs and operations, creating an ongoing structural funding requirement.
Losses And Revenue DeclineLarge losses relative to a small and recently declining revenue base indicate that operating expenses substantially exceed current commercial receipts. This weak earnings structure limits internal reinvestment capacity and makes a durable path to profitability dependent on future revenue growth.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was <AU$0.01 and its highest was AU$0.40 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$3.35M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Feb 25, 2027 which is in 127 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Aug 31, 2026. The company reported -AU$0.026 earnings per share for the quarter.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 334,749,760 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.026 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYP Sentiment 68%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-617.89%
Trailing 12-Months
Asset Growth
-80.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―